Plaque Psoriasis Clinical Trial
Official title:
Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis, a Randomized, Controlled, Open Multicenter Study
Assessment of quality of life after Spa therapy (4 ½ months follow-up) in the treatment of plaque psoriasis: Spa versus usual care in patients with plaque psoriasis.
Psoriasis is one of the most common skin diseases, affecting 2-3% of the general population;
more than 1 million people in France.
This auto-immune erythematosquamous inflammatory dermatosis occurs on a particular genetic
background and has a chronic course. Psoriasis has a history as an indication for
dermatological spa treatment (water cures in the Dead Sea). As these treatments are a
combination of balneotherapy and heliotherapy, many recent studies have attempted to assess
the value and position the relative benefit of each therapeutic element. Over the last four
decades various different phototherapy techniques have been widely used in the treatment of
psoriasis. The thermal option for many psoriasis patients depends on personal choice, or
their doctor's or dermatologist's recommendation. In 1994 only one third of the 16,875 spa
treatments for dermatological conditions (about 5625 cures) were for psoriasis, suggesting
that spa treatment is underused as a treatment for psoriasis. Nobody can challenge the
therapeutic contribution of biotherapy in the treatment of anatomically destructive diseases
such as rheumatoid arthritis and psoriatic arthritis, but the use of these treatments is not
without risk and economic impact. There is thus a need for less intensive treatments that
have little risk of serious side effects and are less expensive.
The use of spa therapy in psoriasis should be understood as complementary and not an
alternative to all other treatments. The choice of treatment is guided by the patient's
characteristics and pathology (concomitant diseases, extent of lesions, treatment history)
and the specialty (adverse effects, cumulative dose). In psoriasis it may be necessary to use
different lines of treatment because psoriasis is a lifetime disease. Side effects of
systemic treatments such as biotherapy, cyclosporine, methotrexate, synthetic retinoids, and
also phototherapy (PUVA and UVB) are cumulative over time. A course of spa treatment should
allow a respite before resorting to other systemic therapy.
However, the spa dermatology still suffers from a lack of large-scale evaluation and
especially an objective assessment using reliable methodologies that limit bias. This is the
purpose of this study.
There are no randomized controlled multicenter clinical trials evaluating spa treatment for
psoriasis, although an Italian non-randomized study included a few dozen patients and
confirmed the clinical benefit of the treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 |